Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies

被引:44
作者
Guichard, SM [1 ]
Mayer, I [1 ]
Jodrell, DI [1 ]
机构
[1] Univ Edinburgh, Pharmacol & Drug Dev Team, Canc Res UK Ctr, Edinburgh EH4 2XR, Midlothian, Scotland
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2005年 / 826卷 / 1-2期
关键词
capecitabine; 5-fluorouracil; quantification; plasma; tumour; liver;
D O I
10.1016/j.jchromb.2005.09.010
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A reverse-phase high-performance liquid chromatography method with electrospray ionization and detection by mass spectrometry is described for the simultaneous determination of capecitabine, its intermediate metabolites (DFCR, DFUR) and the active metabolite 5-fluorouracil in mouse plasma, liver and human xenograft tumours. The method was also cross-validated in human plasma and human tumour for clinical application. The method has greater sensitivity than previously published methods with an equivalent accuracy and precision. It uses less biological material (plasma, tissue) and should therefore be applicable to biopsies in patients treated with capecitabine. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:232 / 237
页数:6
相关论文
共 16 条
[1]   Linear regression for calibration lines revisited: weighting schemes for bioanalytical methods [J].
Almeida, AM ;
Castel-Branco, MM ;
Falcao, AC .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2002, 774 (02) :215-222
[2]   Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients [J].
Gieschke, R ;
Burger, HU ;
Reigner, B ;
Blesch, KS ;
Steimer, JL .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (03) :252-263
[3]   Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study [J].
Hoff, PM ;
Ansari, R ;
Batist, G ;
Cox, J ;
Kocha, W ;
Kuperminc, M ;
Maroun, J ;
Walde, D ;
Weaver, C ;
Harrison, E ;
Burger, HU ;
Osterwalder, B ;
Wang, AO ;
Wong, R .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2282-2292
[4]   CHARACTERIZATION OF MOLECULAR-SPECIES OF LIVER MICROSOMAL CARBOXYLESTERASES OF SEVERAL ANIMAL SPECIES AND HUMANS [J].
HOSOKAWA, M ;
MAKI, T ;
SATOH, T .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1990, 277 (02) :219-227
[5]   Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts [J].
Ishikawa, T ;
Utoh, M ;
Sawada, N ;
Nishida, M ;
Fukase, Y ;
Sekiguchi, F ;
Ishitsuka, H .
BIOCHEMICAL PHARMACOLOGY, 1998, 55 (07) :1091-1097
[6]   Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS [J].
Matuszewski, BK ;
Constanzer, ML ;
Chavez-Eng, CM .
ANALYTICAL CHEMISTRY, 2003, 75 (13) :3019-3030
[7]   Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue [J].
Miwa, M ;
Ura, M ;
Nishida, M ;
Sawada, N ;
Ishikawa, T ;
Mori, K ;
Shimma, N ;
Umeda, I ;
Ishitsuka, H .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (08) :1274-1281
[8]   Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients [J].
Reigner, B ;
Clive, S ;
Cassidy, J ;
Jodrell, D ;
Schulz, R ;
Goggin, T ;
Banken, L ;
Roos, B ;
Utoh, M ;
Mulligan, T ;
Weidekamm, E .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 43 (04) :309-315
[9]  
Reigner B, 1998, CLIN CANCER RES, V4, P941
[10]   Clinical pharmacokinetics of capecitabine [J].
Reigner, B ;
Blesch, K ;
Weidekamm, E .
CLINICAL PHARMACOKINETICS, 2001, 40 (02) :85-104